Latest Articles
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - sharewise.com
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia sharewise.com
Published: Dec. 3, 2025, 5:04 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia - Medical Dialogues
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia Medical Dialogues
Published: Dec. 2, 2025, 5 a.m.
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy - koreabiomed.com
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy koreabiomed.com
Published: Dec. 1, 2025, 6:49 a.m.
Dissecting endometrial cancer complexity in response to standard and targeted therapies - Nature
Dissecting endometrial cancer complexity in response to standard and targeted therapies Nature
Published: Nov. 28, 2025, 5:08 p.m.
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells - News-Medical
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells News-Medical
Published: Nov. 27, 2025, 10:29 a.m.
Link copied to clipboard!